esubmission roadmap v2.0: Industry viewpoint

Similar documents
1 The EU Harmonised technical ectd guidance version 4.0

Annex 2 to the HMA esubmission Roadmap: Implementation of mandatory use of ectd format for regulatory submissions

...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS

Advanced European Regulatory Affairs

Active Substance Master File (ASMF) worksharing procedure

Electronic submission of information on medicinal products in accordance to Article 57(2) requirements: Maintenance submission

Report from the CMDh meeting held on November 2013

General FAQ relating to e-submission for Veterinary Applications

EDQM roadmap for electronic submissions

PSUR and PSUR repository. Legal basis. PSUR/PBRER General comments

Adopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014

TRAINING CALENDAR 2018

The New EU PV Legislation: View from the European Commission

NEWS, KNOWLEGDE, EXPERIENCE & INSPIRATION. ectd. a practical perspective

Standard operating procedure

CMDv/BPG/002. BEST PRACTICE GUIDE for Veterinary Decentralised Procedure (DCP)

Recommendation on duplicate applications in mutual recognition and decentralised procedures

A Dedicated Post Authorisation Measure Submission Form

Implementation of the new pharmacovigilance legislation: Overall update and activities in 2013

Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards

Safeguarding public health. The New PV Legislation. Perspective from a Member State

BEST PRACTICE GUIDE FOR DECENTRALISED AND MUTUAL RECOGNITION PROCEDURES

Capturing the value of SCOPE to the EU Flagship Event London, 23 November 2016

Certification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit

ICH Regulators Forum. Dr Peter Arlett EU

Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective. DIA Europe April Basel, Switzerland

Guide to Renewal of Veterinary Product Authorisations

DRAFT OPINION. EN United in diversity EN. European Parliament 2018/0018(COD) of the Committee on Industry, Research and Energy

Safeguarding public health. The New PV Legislation its Impact on PV & MI

The place of the Certification procedure in 2017 in the EU regulatory framework and beyond. Prague, 19 September 2017

Delivery time frame for the EU portal and EU database

Lessons from the EMA Patient Registries Initiative

Work plan for GCP Inspectors Working Group for 2018

Standard operating procedure

Reflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP Compliance Problems. Outcome of 10 September 2012 Workshop

Detailed guidance for National Scientific- Technical Advice (STA) requests:

GUIDELINES ON eprescriptions DATASET FOR ELECTRONIC EXCHANGE UNDER CROSS-BORDER DIRECTIVE 2011/24/EU RELEASE 1

- Proposal for a Regulation on HTA- Ioana Siska, MD, PhD DG SANTE - Health Systems and Products Medical Products: safety, quality, innovation

Guidelines for new FOCAL POINTS

Good Pharmacovigilance Practice. Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA

- Proposal for a Regulation on HTA- DG SANTE - Health Systems and Products Medical Products: safety, quality, innovation

Submission of new substance and IMP data in the extended EudraVigilance Medicinal Product Dictionary (XEVMPD)

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

lobal armonised ubmission ransport tandard (GHSTS) OECD Project on Harmonisation of Electronic Submissions of Pesticide Dossiers

The Pharmaceutical Risk Assessment Committee (PRAC) of the EMA

Questions and answers about Recycling Processes

MSc REGULATORY AFFAIRS MEDICINES / MEDICAL DEVICES PROSPECTUS

Applicants are reminded that the

Patient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force

Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics Oslo

UNIversal solutions in TELemedicine Deployment for European HEALTH care

***I DRAFT REPORT. EN United in diversity EN. European Parliament 2018/0018(COD)

Overview of ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

<Insert Picture Here> Some Background and What You Should Know and Do Now to Prepare

A Career in Big Pharma. Beatrice Tilt, GSK

INVOLVING PATIENTS IN PHARMACOVIGILANCE EPF TOOLKIT. Susanna Palkonen, EPF Board Member

IMDRF FINAL DOCUMENT. Title: Strategic Assessment of Electronic Submission Messaging Formats

Feedback on SADC Workshop of Industry & Regulators. Luther Gwaza PhD Consultant

REACH Pre-registration Questions and Answers

9/10/2013. Contributions of ECHA to the achievement of the REACH goals. Content of Discussion

ASSESSMENT OF THE CONSOLIDATED ANNUAL ACTIVITY REPORT OF THE AUTHORISING OFFICER FOR THE YEAR 2014

Current and future standardization issues in the e Health domain: Achieving interoperability. Executive Summary

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS

The implementation of the Clinical Trial Regulation (CTR, n 536/2014) in Belgium. and impact on the ethical review process

Guideline on good pharmacovigilance practices (GVP)

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

ectd IV: It s Almost As Fun As Super Bowl XLIX DIA eregulatory and Intelligence Annual Conference Disclaimer

Therefore the provision of medicines is an area for which a Community regulatory framework should be properly supervised to ensure full and

Procedure for handling applications for authorisation and review reports under REACH

BASG / Austrian Medicines and Medical Devices Agency Institute Assessment & Analytics Traisengasse 5, A-1200 Vienna

Patient Registries Initiative Background, Achievements, Next steps

BETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS

MEDICINES CONTROL COUNCIL

Explanatory Notes on Open Innovation Test Beds

Annual report of the Good Clinical Practice Inspectors Working Group 2016

Responsible medication processes ( pharmaceutical care ) and good pharmaceutical practices for improved patients quality of life and batter healthcare

Quality Assurance in Clinical Research at RM/ICR. GCP Compliance Team, Clinical R&D

ETCS Baselines, status, roadmap

Quality Risk Management ICH Q9

Isotretinoin : Review of the Pregnancy Prevention Programme

The Classification and Labelling Inventory. Cefic s viewpoint

Guidance for applicants requesting scientific advice

Post- Fukushima accident. Action plan. Follow-up of the peer review of the stress tests performed on European nuclear power plants

MINIMUM CRITERIA FOR REACH AND CLP INSPECTIONS 1

Completing E2B(R3) Compliance in Total Safety 7

High Level Pharmaceutical Forum

Good Practice Principles:

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES

Update on FDA-EMA QbD Pilot

Study definition of CPD

Harmonisation of Information for Poison Centres

(Non-legislative acts) REGULATIONS

FDA Information Day: who should attend. Detailed Update on the Latest Information for ICSR and IDMP. Individual Case Safety Reports

Novartis Business Services HR University Relations. Regulatory Affairs. Graduate & Postgraduate Program

EUCERD RECOMMENDATIONS on RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS)

Continuous Professional Development of Health Professionals European Context

2008/SOM3/SCCP/002attB Agenda Item: 3(i)

ICT, FET Open LIFT ICT-FP Using Local Inference in Massively Distributed Systems Collaborative Project D 7.1 Quality Assurance Plan

CLP the implementation of GHS in the EU Facts and practical advice

Pharmacovigilance: The patient s Perspective. Souzi Makri Chairperson AGORA EUPATI Fellow Executive Secretary CYPLAR President ENFA

Transcription:

TOPRA Veterinary Medicines Symposium 2017 esubmission roadmap v2.0: Industry viewpoint Patrizia Oelker Boehringer Ingelheim Animal Health ENABLING AND PROMOTING EXCELLENCE IN THE HEALTHCARE REGULATORY PROFESSION

Presentation objectives To review the vet-relevant components of the esubmission Roadmap v2.0 To identify progress made towards reduction of administrative burden To identify further opportunities To raise awareness of practical implications for industry of on-going IT development Relevant esubmission Roadmap components: 1. VNeeS 2. Common repository 3. Integrated submission portal 4. CESSP 5. SPOR

1. VNeeS New milestones for VNeeS mandatory use in national procedures (NP) Q3 2018 for new MAA Q1 2019 for all submissions This is in agreement with IFAH-Europe s position to allow sufficient time for smaller veterinary companies to accommodate to the new requirements

2. Common Repository

2. Common Repository Applicants/MAHs submit applications only once to EMA (via current Gateway/Web Client) No further submissions by other means to any MS Single & centralised archiving of submission packages for the NCA Network with remote access to dossiers - all submission types

3. Integrated submission portal One integrated portal with one single user registration for all procedure types Mandatory use in Q3 2019 Further reduction of administrative burden Strong plea that all NCAs accept CESP-only submissions well before Q3 2019

Preparing an MRP or DCP submission today Member State 1 2 3 4 5 6 7 8 9 n CESP can be used? x x x x x x x x CESP + signed paper copy of eaf? CESP + signed paper copy of CL? eaf may bear text snippet eaf must bear scanned signature Some documents in national language? x x x x x x x x x x x x Payment in advance? x x x Bank account provisioning? Other national req.? x x x x x

4. CESSP data sets CESSP: Common European Single Submission Portal Web user interface Application datasets generated online will replace eaf For new MAA and line extensions: 2018 For variations and renewals in a 2nd step 1st UAT in May 2017

4. CESSP some technicalities Need to convert CESSP output into a human readable file format, also archivable long-term Confirmation sought that VNeeS packages with CESSP output will be accepted by all NCAs for all procedures Having to manage different systems/processes increases complexity and in consequence administrative burden To what extent is IDMP compatibility of CESSP desirable for the veterinary sector?

5. Integration with SPOR What impact for companies?

5.1 OMS impact Will be integrated with eaf and CESSP After a transition period, current free text fields for MA applicant / MA Holder / manufacturers will be replaced by drop down lists. Pre-registration of Org. details in OMS by Industry ahead of submission will be needed Change will be validated by EMA team Check OMS before starting eaf compilation! Factor more time in case a change request to EMA must be filed Refer to EMA document on SPOR SLAs

5.2 RMS impact Already integrated with eaf Will be integrated with CESSP Similar to current process: Industry to request registration of new/updated terms before regulatory submission Change will be validated by EMA team Check RMS before starting eaf compilation Factor more time in case a change request to EMA must be filed Refer to EMA document on SPOR SLAs Refer to EMA explanatory document linked to each referentials list

5.3 SMS & PMS Management Systems for Substances and Products Integration of SMS with eaf and CESSP will require preregistration of substances in SMS IFAH-Europe s vision: single data entry in CESSP (i.e. PMS consumes product data from CESSP) However, discussions at the EMA working groups are largely dominated by Human Pharma concerns and needs (legal obligation in the EU to comply with ISO IDMP requirements)

5.3 SMS & PMS IFAH-Europe calls for simple and cost effective IT solutions for the veterinary domain to reduce administrative burdens ISO IDMP is not a requirement for the veterinary sector SMS & PMS implementation must be: appropriately adapted to AH considering size and requirements only to the extent necessary thereby contributing to the goal of the EU Commission proposal for a Regulation on VMPs* *2014/0257 (COD)

Concluding remarks 100% IFAH-Europe calls for: simple and cost-effective IT solutions, harmonisation of tools amongst various procedures (CP, MRP/DCP, NP). Goal of the EC proposal: reduce administrative burdens, >> increasing the availability of VMPs and stimulating competitiveness. 6% 13% 3% *Assessment of the Impact of the Revision of Veterinary Pharmaceutical Legislation, 11 July 2011

EU esubmission Roadmap v2.0 Thank you for your attention

Acronyms CESP: Common European Submission Platform CESSP: Common European Single Submission Platform CL: Cover Letter eaf: electronic Application Form IDMP: IDentification of Medicinal Products IFAH-Europe: International Federation for Animal Health-Europe OMS: Organisations Management System MAA: Marketing Authorisation Application NCA: National Competent Authority PMS: Products Management System RMS: Referentials Management System SLA: Service Level Agreement SMS: Substances Management System SPOR: Substances, Products, Organisations, Referentials UAT: User Acceptance Testing VNeeS: Veterinary Non-eCTD electronic Submission

Back up slides Link to the EMA esubmission website http://esubmission.ema.europa.eu/tiges/vetesub.htm Link to the esubmission Roadmap v2.0 http://esubmission.ema.europa.eu/tiges/cmbdocumentation.h tml

esubmission Roadmap v1.0 (reflecting final adopted version 1.0 dated 141107) draft esub Roadmap NCA & industry survey esub Roadmap Adoption Ongoing/optional Mandatory Use of ectd v.4 All submissions in CP (human) in ectd New MAA in DCP (human) in ectd Use of NeeS and ectd in DCP and MRP (human) All submissions in MRP (human) New MAA in DCP and MRP (human) in ectd All other MRP submissions (human) All submissions in CP, DCP and MRP (human) in ectd Use of VNeeS in CP, DCP and MRP (vet) New MAA in CP and DCP (vet) in VNeeS All other in CP and all MRP submissions (vet) All submissions in CP, DCP and MRP (vet) in VNeeS egateway (CP) (human and vet) CESP (human and vet) egateway (CP, human) Use of eaf in all procedures (human and vet) in CP in all other procedures Single submission portal - combined CESP/Gateway in CP (human) Single submission portal - combined CESP/Gateway in all other procedures (human and vet) eaf in all procedures (human and vet) Single Submission Portal with integration of eaf for all submissions (human and vet) NCA use of Common Repository for CP submissions (human) NCA use of Common Repository for all CP submissions (human) Use of PSUR Repository for CAPs and NAPs (human) Use of PSUR Repository for all CAPs and NAPs (human) 2013 2014 2015 2016 2017 2018 22

esubmission Roadmap v1.0 (reflecting final adopted version 1.0 dated 141107) draft esub Roadmap NCA & industry survey esub Roadmap Adoption Ongoing/optional Mandatory Use of ectd v.4 All submissions in CP (human) in ectd New MAA in DCP (human) in ectd Use of NeeS and ectd in DCP and MRP (human) All submissions in MRP (human) New MAA in DCP and MRP (human) in ectd All other MRP submissions (human) All submissions in CP, DCP and MRP (human) in ectd Use of VNeeS in CP, DCP and MRP (vet) New MAA in CP and DCP (vet) in VNeeS All other in CP and all MRP submissions (vet) All submissions in CP, DCP and MRP (vet) in VNeeS egateway (CP) (human and vet) CESP (human and vet) egateway (CP, human) Use of eaf in all procedures (human and vet) in CP in all other procedures Single submission portal - combined CESP/Gateway in CP (human) Single submission portal - combined CESP/Gateway in all other procedures (human and vet) eaf in all procedures (human and vet) Single Submission Portal with integration of eaf for all submissions (human and vet) NCA use of Common Repository for CP submissions (human) NCA use of Common Repository for all CP submissions (human) Use of PSUR Repository for CAPs and NAPs (human) Use of PSUR Repository for all CAPs and NAPs (human) 2013 2014 2015 2016 2017 2018

IDMP (IDentification of Medicinal Products) SPOR is used to implement ISO IDMP in the EU The ISO IDMP standards were developed in response to a worldwide demand for internationally harmonized specifications for medicinal products (authorized and investigational) In the EU, for Human Pharma: ISO IDMP is a legal requirement Pharmacovigilance Legislation, in particular EC Regulation 1235/2010, and Commission Implementing Regulation 520/2012 (= the IDMP Regulation ) ISO Standards should be implemented in other regions/ countries too (US, Canada, Switzerland, ) Key Goals: - standardise the information, - have interoperable systems, - enhance patient safety (PhV!)